Common questions about Hexacima (FAQ)
Q: What are the benefits of getting the Hexacima shot instead of separate vaccines?
A: Hexacima is a combination vaccine that protects against six diseases in a single injection. Official regulatory documents note that this format simplifies the immunization schedule for infants, which is recognized as a convenience and public health advantage.
Q: What is the difference between Hexacima and other 5-in-1 or 6-in-1 vaccines?
A: Official regulatory studies compared the immune response (immunogenicity) of Hexacima to other established combination vaccines. This comparison confirms that Hexacima is comparable in its ability to help the body develop protective antibodies. Details of its specific antigens and composition are available in the official product information.
Q: What ingredients are in the Hexacima vaccine?
A: The active ingredients are the parts of the bacteria and viruses that protect against the six diseases. The vaccine also contains an aluminum compound, which acts as an adjuvant to help the immune system react more strongly. Trace amounts of substances used in manufacturing, such as formaldehyde and antibiotics (like neomycin), may also be present.
Q: Are there any preservatives in Hexacima?
A: The official list of excipients and trace residuals provided in regulatory documents confirms that the Hexacima vaccine does not contain common preservatives such as mercury or thiomersal.
Q: Are there any specific medicines that should be avoided around the time of the Hexacima shot?
A: Official documents state that the Varicella (chickenpox) vaccine is generally avoided at the same time as Hexacima due to potential interference with the immune response. Additionally, treatments that suppress the immune system, such as high-dose corticosteroids or chemotherapy, may reduce the vaccine’s effectiveness, and immunization is officially recommended to be postponed until the end of such treatment.
Q: Can children with a history of seizures receive Hexacima?
A: Regulatory warnings state that if a child has an uncontrolled neurologic disorder or uncontrolled epilepsy, the pertussis component in Hexacima is officially contraindicated. A history of febrile convulsions (seizures related to fever) alone is not a contraindication, but close follow-up is recommended in the regulatory documents.
Q: What if a child misses one of the scheduled Hexacima doses?
A: The vaccine is given according to a precise schedule with minimum time intervals between doses. If a dose is missed, national immunization guidelines generally advise that there is no need to restart the entire primary series, but guidance on the appropriate catch-up schedule is determined by a healthcare professional.
Q: How effective is Hexacima in preventing the targeted diseases?
A: Studies confirm that the vaccine generates levels of protective antibodies (known as the Seroprotection Rate) in infants that are comparable to those produced by other established vaccines. This strong antibody response is an accepted surrogate measure for clinical protection against the six diseases.
Q: How long does the immunity from Hexacima last?
A: The immune protection lasts until the necessary booster dose is administered later in childhood. While the clinical trials have limited long-term follow-up data extending past the toddler years, the vaccine is expected to provide durable, long-term protection.
Q: Why do doctors recommend the Hexacima vaccine over individual shots?
A: Health authorities endorse the use of this combined vaccine as an efficient public health strategy. The ready-to-use, single-injection format simplifies the immunization process and helps ensure timely and complete protection against six critical childhood diseases.
Q: Is Hexacima licensed for use in adults?
A: No, Hexacima is officially indicated and licensed only for the primary and booster vaccination of infants and toddlers, beginning at six weeks of age. Regulatory documents state that its use is not established in children over 24 months of age or in adults.
Q: Can pregnant women be given the Hexacima vaccine?
A: The Hexacima vaccine is not intended for use in women of child-bearing age. The official product information states that clinical data regarding its use during pregnancy or while breastfeeding are not available.
Q: What should parents do if their child is very fussy or crying after the Hexacima shot?
A: Irritability and general crying are listed as very common or common side effects. However, official safety warnings advise seeking medical attention if the child exhibits persistent, inconsolable crying that lasts for three hours or more within 48 hours of the vaccination.
Q: Does the Hexacima vaccine contain mercury or thiomersal?
A: Based on the official list of ingredients and excipients provided in regulatory documents, the Hexacima vaccine does not contain thiomersal (mercury).
Q: Is it normal for a child to sleep more than usual after getting Hexacima?
A: Yes, regulatory documents list somnolence, which is increased drowsiness or sleeping more than usual, as a common adverse reaction following vaccination.
Q: Can I breastfeed my baby immediately after they receive the Hexacima vaccine?
A: The regulatory documents state that data on the use of the vaccine during lactation are not available, as it is primarily intended for the infant population. Furthermore, there is no specific guidance regarding breastfeeding provided in the regulatory documents.
Q: What is the recommended storage temperature for Hexacima before administration?
A: The vaccine must be stored strictly in a refrigerator between 2 C and 8 C. It is crucial that the product is never frozen, as freezing will cause it to be discarded. Administration should occur as soon as reasonably possible after removal for injection, in line with standard practice.
Q: How soon after the first dose does protection from Hexacima begin?
A: While some immune response may begin earlier, official documents indicate that a full protective antibody response is typically achieved one month after the last dose of the primary vaccination series has been completed.
Q: Can Hexacima interact with steroid medications?
A: Yes, official regulatory information indicates that immunosuppressive therapies, including corticosteroids (e.g., high doses), can reduce the effectiveness of the vaccine. If a child is on such a medication, vaccination may need to be postponed until the treatment is finished.
Q: Can Hexacima cause temporary loss of appetite?
A: Yes, loss of appetite, also known as anorexia, is listed in official regulatory documents as a very common adverse reaction following the administration of Hexacima.
Q: Can Hexacima be given to an older child who hasn't been vaccinated yet?
A: The vaccine is officially approved and studied for use only up to 24 months of age. For older children who have not completed their vaccinations, alternative vaccines or approaches, designed and studied for older age groups, may be utilized for catch-up schedules.
Q: How is the safety of Hexacima monitored after it is released to the public?
A: The safety is continuously monitored through a system called pharmacovigilance, or post-marketing surveillance. This process involves the collection and review of all reported adverse reactions from healthcare professionals and patients after the vaccine is made available.
Q: What should I tell the doctor before my child receives Hexacima?
A: In preparation for the vaccination, the doctor should be informed about any history of serious allergic reactions, any prior severe neurological events (encephalopathy) following a pertussis-containing vaccine, or if the child has any uncontrolled neurological disorders. You must also mention if the child has a current moderate or severe fever or infection.
Q: How long should I wait to give my child other vaccines after Hexacima?
A: Official documents confirm that Hexacima can be safely given at the same time as several other common pediatric vaccines, such as MMR and Pneumococcal. For vaccines where simultaneous administration is not recommended, guidance on the appropriate interval should be sought from a healthcare provider.
Q: Do all Hexacima side effects need to be reported to a doctor?
A: While official documents detail all known side effects, regulatory documents advise that severe allergic reactions or rare, serious events should be immediately reported. Any side effect that is severe or causes concern should be reported.
Q: Is there official information available about the development history of Hexacima?
A: Yes, the official Public Assessment Reports published by regulatory bodies like the EMA contain a detailed overview of the vaccine's development. This includes summaries of the clinical trials regarding immunogenicity and safety that were submitted for the vaccine’s authorization.
